1. Home
  2. PAYO vs KOD Comparison

PAYO vs KOD Comparison

Compare PAYO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Payoneer Global Inc.

PAYO

Payoneer Global Inc.

HOLD

Current Price

$7.12

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

N/A

Current Price

$37.50

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAYO
KOD
Founded
2005
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
PAYO
KOD
Price
$7.12
$37.50
Analyst Decision
Strong Buy
Buy
Analyst Count
8
7
Target Price
$7.69
$35.43
AVG Volume (30 Days)
3.5M
554.5K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$1,052,774,000.00
N/A
Revenue This Year
$7.15
N/A
Revenue Next Year
$10.28
N/A
P/E Ratio
$142.00
N/A
Revenue Growth
7.68
N/A
52 Week Low
$4.08
$8.30
52 Week High
$7.18
$47.84

Technical Indicators

Market Signals
Indicator
PAYO
KOD
Relative Strength Index (RSI) 58.40 41.64
Support Level $7.08 $32.93
Resistance Level $7.16 $46.29
Average True Range (ATR) 0.03 2.44
MACD -0.01 -0.40
Stochastic Oscillator 64.29 26.66

Price Performance

Historical Comparison
PAYO
KOD

About PAYO Payoneer Global Inc.

Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: